Jaguar Health’s parent company, Napo Pharmaceuticals, received a new Australian patent on November 24, 2025 for methods that use the plant‑derived active ingredient crofelemer to treat short bowel syndrome, bile acid diarrhea, and diarrhea associated with small‑intestine resection or gallbladder removal.
The patent extends global exclusivity for crofelemer‑based therapies in the rare pediatric intestinal‑failure market, a key element of Jaguar’s strategy to secure non‑dilutive partnership funding and accelerate clinical milestones for its rare‑disease program. By locking in IP protection, the company strengthens its competitive moat and positions itself to negotiate more favorable licensing or collaboration terms with payers, distributors, and potential partners in the coming months.
Jaguar Health reported Q3 2025 revenue of $X million, a 4% year‑over‑year increase, and a net loss of $9.5 million, an improvement from the $9.9 million loss reported in the same quarter last year. Gross margin remained strong at Y%, but operating margin was negative, reflecting continued investment in research and development and marketing expenses. The company’s free‑cash‑flow yield is negative, and cash burn remains high, underscoring the financial headwinds that accompany the patent’s strategic benefits.
CEO Lisa Conte said the new patent “expands the international IP protection supporting crofelemer’s development in short bowel syndrome with intestinal failure.” While the patent is a positive milestone, Jaguar’s financial profile – high cash burn, negative free‑cash‑flow, and significant debt – highlights the need for continued partnership and funding to sustain its rare‑disease pipeline.
The patent grant is a material regulatory event that enhances Jaguar Health’s IP portfolio and positions the company for future licensing opportunities, but investors should weigh this upside against the company’s ongoing cash‑flow challenges and the need for additional capital to support its clinical and commercial development plans.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.